Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans.

Genetics and Molecular Biology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, United States
Blood (Impact Factor: 9.78). 09/2012; DOI: 10.1182/blood-2012-02-400937
Source: PubMed

ABSTRACT We conducted a gene therapy trial in 10 patients with adenosine deaminase-deficient severe combined immunodeficiency (ADA-deficient SCID) using two slightly different retroviral vectors for the transduction of patients' bone marrow CD34+ cells. Four subjects were treated without pre-transplant cytoreduction and remained on ADA enzyme replacement therapy (ERT) throughout the procedure. Only transient (months), low level (<0.01%) gene marking was seen in peripheral blood mononuclear cells (PBMC) of two older subjects (15 and 20 years old), whereas some gene marking of PBMC has persisted for the past nine years in two younger subjects (4 and 6 years). Six additional subjects were treated using the same gene transfer protocol, but after withdrawal of ERT and administration of low-dose busulfan (65-90 mg/m(2)). Three of these remain well, off ERT (5, 4, and 3 years post-procedure), with gene marking in PBMC of 1-10%, and ADA enzyme expression in PBMC near or in the normal range. Two subjects were restarted on ERT due to poor gene marking and immune recovery and one had a subsequent allogeneic hematopoietic stem cell transplant. These studies directly demonstrate the importance of providing non-myeloablative pre-transplant conditioning to achieve therapeutic benefits with gene therapy for ADA-deficient SCID.


Available from: Kit L. Shaw, Apr 04, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary Immunodeficiencies (PIDs) have represented a paradigmatic model for successes and pitfalls of haematopoietic stem cells gene therapy (HSC-GT). First clinical trials performed with gamma retroviral vectors (γ-RV) for adenosine deaminase deficiency (ADA-SCID), X-linked SCID (SCID-X1), and Wiskott-Aldrich Syndrome (WAS) showed that gene therapy is a valid therapeutic option in patients lacking a HLA-identical donor. No insertional mutagenesis events have been observed in > 40 ADA-SCID patients treated so far in the context of different clinical trials worldwide, suggesting a favorable risk benefit ratio for this disease. On the other hand, the occurrence of insertional oncogenesis in SCID-X1, WAS and CGD RV clinical trials, prompted the development of safer vector construct based on self-inactivating (SIN) retroviral or lentiviral vectors (LVVs). Here we will present the recent results of LVV mediated gene therapy for WAS showing stable multilineage engraftment leading to haematological and immunological improvement, and discuss the differences with respect to the WAS RV trial. We will also describe recent clinical results of SCID-X1 gene therapy with SIN γ-RV and the perspectives of targeted genome editing techniques, following early preclinical studies showing promising results in terms of specificity of gene correction. Finally, we provide an overview of the gene therapy approaches for other PIDs and discuss its prospects in relation to the evolving arena of allogeneic transplant.
    Human gene therapy 04/2015; 26(4). DOI:10.1089/hum.2015.047 · 3.62 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A definitive understanding of survival and differentiation potential in humans of T cell subpopulations is of paramount importance for the development of effective T cell therapies. In particular, uncovering the dynamics in vivo in humans of the recently described T memory stem cells (TSCM) would be crucial for therapeutic approaches that aim at taking advantage of a stable cellular vehicle with precursor potential. We exploited data derived from two gene therapy clinical trials for an inherited immunodeficiency, using either retrovirally engineered hematopoietic stem cells or mature lymphocytes to trace individual T cell clones directly in vivo in humans. We compared healthy donors and bone marrow-transplanted patients, studied long-term in vivo T cell composition under different clinical conditions, and specifically examined TSCM contribution according to age, conditioning regimen, disease background, cell source, long-term reconstitution, and ex vivo gene correction processing. High-throughput sequencing of retroviral vector integration sites (ISs) allowed tracing the fate of more than 1700 individual T cell clones in gene therapy patients after infusion of gene-corrected hematopoietic stem cells or mature lymphocytes. We shed light on long-term in vivo clonal relationships among different T cell subtypes, and we unveiled that TSCM are able to persist and to preserve their precursor potential in humans for up to 12 years after infusion of gene-corrected lymphocytes. Overall, this work provides high-resolution tracking of T cell fate and activity and validates, in humans, the safe and functional decade-long survival of engineered TSCM, paving the way for their future application in clinical settings. Copyright © 2015, American Association for the Advancement of Science.
    Science translational medicine 02/2015; 7(273):273ra13-273ra13. DOI:10.1126/scitranslmed.3010314 · 14.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The development of a T-cell receptor excision circle (TREC) assay utilizing dried blood spots in universal newborn screening has allowed the early detection of T-cell lymphopenia in newborns. Diagnosis of severe combined immunodeficiency (SCID) in affected infants in the neonatal period, while asymptomatic, permits early treatment and restoration of a functional immune system. SCID was the first immunodeficiency disease to be added to the Recommended Uniform Screening Panel of Core Conditions in the United States in 2010, and it is now implemented in 26 states in the U.S. This review covers the development of newborn screening for SCID, the biology of the TREC test, its current implementation in the U.S., new findings for SCID in the newborn screening era, and future directions. Copyright © 2015 Elsevier Inc. All rights reserved.
    Seminars in perinatology 04/2015; 39(3). DOI:10.1053/j.semperi.2015.03.004 · 2.42 Impact Factor